Gobbling up big biotech firms with proven drugs in the marketplace, rather than cheaper but more speculative start-ups, gets around the difficulties of winning regulatory approval for a new drug.

• 针对于新药通过审批的难度来说，监管部门更倾向于将大型生物制品公司的成熟产品尽数投入市场，而不是批准低成本的雏形投机到市场中。